Theacrine
Theacrine (1,3,7,9-tetramethyluric acid) is a stimulant of the methylurate purine alkaloid class. It is a close structural relative of caffeine, built on the same purine scaffold with one extra oxidation and methylation step.[1] It blocks adenosine receptors that promote sleep and boosts dopamine activity, producing wakefulness and mental drive.[2]
Theacrine (1,3,7,9-tetramethyluric acid) is a naturally-occurring stimulant of the methylurate purine alkaloid class. It is a close structural relative of caffeine, differing by one oxidation and one methylation on the purine scaffold.[1] Theacrine is an adenosine A₁ and A₂A receptor antagonist, producing its effects by blocking sleep-promoting signaling and facilitating dopamine activity.[2]
Theacrine was first identified in tea leaves in 1937 but attracted little attention until researchers discovered it accumulates as the dominant alkaloid in Kucha tea, a wild Chinese variety.[3] Its mechanism was established in 2012, and commercial launch as TeaCrine® followed in 2014.[2][4] It is sold worldwide today as an unscheduled dietary supplement.
Subjective effects include wakefulness, sharper focus, increased motivation, and mild mood elevation. The experience is cleaner and more sustained than Caffeine — a steady mental clarity without the jittery edge, lasting well beyond a typical caffeine window.[5] At higher doses, stomach discomfort, a racing heartbeat, and hand tremor are reported.[6]
Theacrine shows no evidence of physical dependence, and no overdose or serious adverse event has been reported.[7] Blood pressure rises and cortisol elevates at doses above typical supplementation ranges, but unlike most stimulants, effects do not diminish with repeated use — so there is no pressure to escalate the dose.[6][8] Human safety data extend only to eight weeks at 300 mg/day, and long-term effects remain uncharacterized.
History[edit]
Discovery
Theacrine was first identified as a minor constituent of Camellia sinensis tea leaves in 1937.citation needed The compound attracted little pharmacological interest for decades. Renewed attention came when Chinese researchers found that Camellia assamica var. kucha — a wild tea variety native to southern China — accumulates theacrine as its dominant purine alkaloid at approximately 2.8% by dry weight, effectively replacing caffeine.[3]
Pharmacological characterization and commercial development
The first peer-reviewed pharmacological study appeared in 2012, establishing that theacrine blocks adenosine receptors and engages dopamine pathways to produce stimulant effects.[2] Compound Solutions launched TeaCrine® in June 2014,[4] backed by a U.S. patent on theacrine-based supplement formulations.[9]
Modern research
Since 2015, multiple controlled trials have examined theacrine's effects on cognition, mood, exercise performance, and safety. It remains commercially available worldwide as an unscheduled supplement ingredient, with no regulatory authority having initiated scheduling proceedings.
The name theacrine derives from Thea, an older botanical synonym for the tea genus Camellia. In Kucha tea, it produces a distinctive bitter taste by activating the human bitter taste receptor hTAS2R14.[10]
Chemistry[edit]
Structural class
Theacrine belongs to the methylurate subclass of purine alkaloids — one oxidation step beyond the methylxanthine family that includes caffeine and theobromine. It is built on a uric acid scaffold fully methylated at four positions, carrying an extra oxygen (a C8 carbonyl) where caffeine has a C8-H bond.[1] Plants produce theacrine directly from caffeine through C8 oxidation followed by N9 methylation.[3]
Molecular properties
| Molecular formula | C₉H₁₂N₄O₃ |
| Molecular weight | 224.22 g/mol |
Theacrine carries no electrical charge at physiological pH[12] and has no stereocenters. It occurs at pharmacologically meaningful concentrations in Kucha tea (Camellia assamica var. kucha) at approximately 2.8% by dry weight,[3] and in smaller amounts in cupuaçu fruit and certain Coffea species.[7][13]
Pharmacology[edit]
Mechanism of action
Theacrine blocks adenosine receptors — the brain's endogenous signals that build sleep pressure and suppress wakefulness. This releases a brake on dopamine activity, amplifying motivation and drive.[2] At low doses in animals, an opposing sedative effect appears;[14] at doses used in human supplementation, the stimulant effect predominates.
Pharmacokinetics
Oral theacrine reaches peak concentration within about 30 minutes. The half-life is approximately 21 hours — far longer than caffeine's 3–6 hours — so effects persist well beyond the perceived peak and daily dosing causes accumulation.[5]
Caffeine co-administration raises theacrine's blood levels by improving absorption, without changing how quickly the body clears it.[15] The metabolic pathway is unconfirmed, but CYP1A2 enzyme involvement is inferred from analogy with caffeine.[16]
Neuroscience[edit]
Where it acts
Theacrine's stimulant effects converge on the brain's motivational circuitry. Blocking adenosine receptors in the striatum removes a brake on dopamine signals running from the ventral tegmental area to the nucleus accumbens.[2] This amplifies wanting — motivation and goal-directed drive — more than pleasure.
Why it matters
Animal studies suggest theacrine may promote the growth of new brain cells in the hippocampus,[17] protect dopamine-producing neurons,[18] and activate antioxidant defenses after injury.[19] Whether any of these effects occur in humans at supplementation doses is unknown.
Unlike most stimulants that engage dopamine pathways, theacrine does not produce tolerance or sensitization with repeated dosing in animals.[2] An 8-week human trial confirmed the same absence of habituation.[7] The reason the brain does not adapt is not understood.
- Why does theacrine not produce tolerance? The 8-week non-habituating profile is its most distinctive pharmacological feature,[7] yet the mechanism remains entirely hypothetical.
- Does the low-dose sedation seen in rodents occur in humans? It has not been systematically tested in dose-finding studies.
- No formal receptor binding data have been published. Such studies would clarify whether theacrine binds directly to receptors or acts indirectly.
Subjective Effects[edit]
Theacrine produces a steady, sustained cognitive stimulation — clear-headed wakefulness that builds gradually and holds without sharp peaks or crashes. The experience is primarily mental: focus sharpens and motivation increases, with only mild physical activation. Structured tasks make better use of the stimulation than unstructured time.
Compared to caffeine, theacrine runs cleaner and longer — less anxious, more even, and without the tolerance that gradually erodes caffeine's effect over weeks of daily use.[7][5] It sits below prescription wakefulness agents in raw potency but above caffeine in consistency across repeated use.
First identified as a minor tea constituent in 1937, theacrine remained pharmacologically uncharacterized until its adenosine and dopamine receptor mechanisms were established in 2012.[2] Commercial launch as the branded supplement TeaCrine® in 2014[3] catalyzed multiple human clinical trials spanning cognition, exercise performance, and safety. It is sold worldwide as an unscheduled dietary supplement ingredient.
Subjective effects include wakefulness, cognitive enhancement, motivation enhancement, and mild mood elevation. The experience is one of sustained, clean stimulation — a steady cognitive sharpening without the jittery anxiety that Caffeine produces at equivalent doses, and with notably prolonged duration.[4] Gastrointestinal discomfort, perceived heart racing, and hand tremor are reported unsought effects at higher doses.[5]
Theacrine shows no evidence of physical dependence, and no serious adverse events or overdose cases have been reported.[6] Its most distinctive safety feature is the absence of tolerance — an 8-week trial detected no habituation to energy or focus effects, a property unmatched by most adenosine-targeting stimulants.[6] Human safety data extend only to eight weeks at 300 mg/day; formal receptor binding data, metabolic pathways, and long-term effects remain uncharacterized.
History[edit]
Discovery
Theacrine was first identified as a minor constituent of Camellia sinensis leaves in 1937.citation needed The compound attracted little pharmacological interest for decades, remaining an obscure natural product of tea chemistry. Renewed attention came in the late 1990s when Chinese researchers discovered that Camellia assamica var. kucha — a wild tea variety native to southern China — accumulated theacrine as its dominant purine alkaloid at approximately 2.8% by dry weight, effectively replacing caffeine.[7]
Pharmacological characterization and commercial development
The first peer-reviewed pharmacological study appeared in 2012, when Feduccia and colleagues demonstrated adenosine receptor antagonism and dopaminergic involvement in theacrine's stimulant effects using rat models.[2] Compound Solutions, Inc. launched TeaCrine® — a branded, nature-identical form — in June 2014 under an exclusive distribution license,[3] and a U.S. patent (US10272091B2) covering theacrine-based supplement formulations was subsequently granted.[8]
Modern research
From 2015 onward, multiple randomized controlled trials have examined theacrine's effects on cognition, mood, exercise performance, and safety in healthy populations. The compound remains commercially available as an unscheduled dietary supplement ingredient in all major markets, with no regulatory agency having initiated scheduling proceedings or drug development program targeting therapeutic indications.
The name theacrine derives from Thea, an older botanical synonym for the tea genus Camellia, reflecting the compound's origin in tea leaves. In Kucha tea — the only beverage where theacrine predominates over caffeine — it contributes a distinctive bitter taste through activation of the human bitter taste receptor hTAS2R14.[9]
Chemistry[edit]
Structural class
Theacrine belongs to the methylurate subclass of purine alkaloids. Its parent scaffold is uric acid (2,6,8-trioxopurine), fully methylated at positions N1, N3, N7, and N9. This places it one oxidation step beyond the methylxanthine class that includes caffeine, theobromine, and theophylline — theacrine carries a C8 carbonyl where caffeine has a C8-H bond.[1]
Structurally, theacrine is the direct biosynthetic product of caffeine: C8 oxidation yields 1,3,7-trimethyluric acid, followed by N9 methylation to produce the final tetramethylated compound.[7] The two molecules differ by one oxygen addition and one methyl group — a minimal structural change that preserves shared pharmacological targets while producing distinct pharmacokinetic and tolerance profiles.
Molecular properties
| Molecular formula | C₉H₁₂N₄O₃ |
| Molecular weight | 224.22 g/mol |
The purine ring carries three carbonyl groups at positions C2, C6, and C8, and four N-methyl substituents. The molecule is electrically neutral at physiological pH,[11] possesses no stereocenters, and exists as a single achiral constitutional isomer.
Natural occurrence
Theacrine occurs at pharmacologically meaningful concentrations in Camellia assamica var. kucha (Kucha tea), where young leaves accumulate approximately 2.8% by dry weight — replacing caffeine as the dominant purine alkaloid.[7] It is also found in the fruit of Theobroma grandiflorum (cupuaçu) and in minor quantities in certain Coffea species.[6][12]
No peer-reviewed data on theacrine's aqueous solubility, partition coefficient, or solid-state stability have been published. Commercial preparations are supplied as a white to off-white crystalline powder.[13]
Pharmacology[edit]
Mechanism of action
Theacrine's stimulant effects operate through two converging systems: adenosine receptor antagonism and dopaminergic facilitation.
Adenosine receptor antagonism is the primary mechanism. Theacrine blocks both A₁ and A₂A adenosine receptors, counteracting the brain's endogenous sleep-promoting signals.[2] This parallels caffeine's core action, though theacrine's relative selectivity between the two receptor subtypes has not been quantified.
Dopaminergic involvement amplifies the stimulant effect. Theacrine-driven locomotor activation in animals is reduced by dopamine D₁ and D₂ receptor blockers, and direct infusion into the nucleus accumbens produces dose-dependent behavioral activation.[2] Whether theacrine acts directly on dopamine receptors or modulates dopaminergic transmission indirectly through adenosine–dopamine interactions has not been resolved.
An important dose-dependent duality appears in animal studies. At low doses, theacrine acts as a sedative, increasing sleep duration through apparent adenosine agonist-like activity.[14] At higher doses, stimulant effects predominate via adenosine antagonism and dopaminergic mechanisms.[2] This biphasic profile has not been formally characterized in humans, though the absence of sedative reports at typical supplementation doses (100–300 mg) suggests the stimulant phase predominates at these exposures.
Pharmacokinetics
Oral theacrine is rapidly absorbed, reaching peak salivary concentrations within 30 minutes of administration.[4] The half-life is approximately 21 hours — substantially longer than caffeine's 3–6 hours.[4] This extended half-life implies significant accumulation with daily dosing and a prolonged window of pharmacological action.
Caffeine co-administration meaningfully increases theacrine's systemic exposure — both peak concentration and total exposure rise — without altering its elimination rate, likely through enhanced presystemic bioavailability.[15] Habitual caffeine consumers may therefore experience stronger theacrine effects than caffeine-naive individuals at equivalent doses. Theacrine does not affect caffeine's own pharmacokinetics.
No direct metabolic pathway studies have been published. CYP1A2 involvement is structurally inferred from analogy with caffeine but remains unconfirmed.[16] Absolute oral bioavailability has not been measured in humans.
Neuroscience[edit]
Where it acts
Theacrine's stimulant effects converge on the mesolimbic pathway, with the nucleus accumbens identified as a primary effector site.[2] Adenosine antagonism in the striatum disinhibits dopaminergic signaling along the ventral tegmental area–nucleus accumbens projection, enhancing motivational drive and behavioral activation. This maps onto the incentive salience framework: theacrine enhances wanting — the motivational component of reward — without pronounced euphoria, consistent with the subjective profile of increased drive rather than pleasure.
Why it matters
Beyond acute stimulation, animal studies have identified multiple neuroprotective pathways. Theacrine promotes hippocampal neurogenesis through the BDNF/TrkB signaling cascade in chronic stress models,[17] protects dopaminergic neurons via SIRT3 activation in Parkinson's disease models,[18] and activates the Nrf2 antioxidant pathway in stroke models.[19] Whether any of these effects translate to humans at supplementation doses is unknown.
The absence of tolerance or sensitization in chronically dosed animals[2] is pharmacologically distinctive. Most stimulants that engage the mesolimbic dopamine system produce progressive neuroadaptation with repeated exposure — theacrine does not, suggesting a unique receptor interaction that avoids triggering compensatory regulation.
- Why does theacrine not produce tolerance? The 8-week non-habituating profile is its most distinctive pharmacological feature,[6] yet the underlying mechanism remains entirely hypothetical.
- Is the biphasic dose-response (low-dose sedation, high-dose stimulation) present in humans? It is documented in rodents but has not been systematically examined in human dose-finding studies.
- No formal receptor binding affinities have been published for any target. Radioligand binding studies would clarify selectivity and distinguish direct binding from indirect modulation.
Subjective Effects[edit]
Theacrine's experiential character centers on sustained cognitive stimulation — a steady-state wakefulness and motivational clarity that builds gradually and persists without the peaks and troughs common to caffeine. The experience is primarily mental rather than physical: enhanced focus and task persistence define the profile, with only mild mood elevation and minimal somatic activation. Set and setting exert less influence than with psychedelic or empathogenic compounds, though context shapes whether stimulation is experienced as productive focus or restless activation.
Compared to Caffeine, theacrine offers a cleaner, more sustained trajectory — longer-acting[4] with an anxiety-sparing profile and without the tolerance development that diminishes caffeine's effects over weeks of daily use.[6] It sits below prescription wakefulness-promoting agents in raw efficacy but above caffeine in consistency of effect across repeated use.
Effect Grid
Clear stimulation with enhanced focus, motivation, and sustained wakefulness. This is the primary experiential window documented in clinical trials (100–200 mg). Mild mood elevation — cognitive euphoria and increased motivation to engage with tasks — without anxiety escalation. Thought acceleration is subtle but present.
Physical effects remain modest. Cardiovascular parameters stay within normal limits per 8-week safety data at 200 mg/day. Mild appetite suppression may occur. No significant gastrointestinal effects at this range.
Effects are sustained over several hours with a gradual, smooth resolution. Non-habituating over weeks of daily use — no dose escalation needed to maintain efficacy.
Modeled from the effect's dose-dependence curve — not per-substance measurements.
Increased urination · Physical fatigue · Nausea · Headache · Restlessness · Dehydration sensation · Pain suppression · Bruxism · Sexual arousal enhancement · Sedation
Restlessness · Dehydration sensation · Pain suppression · Bruxism · Sexual arousal enhancement · Sedation
Cognitive euphoria · Information processing enhancement · Cognitive fatigue · Memory enhancement
Timeline
Initial absorption phase. Theacrine reaches salivary Tmax within 30 minutes. Minimal subjective effects — a subtle shift in baseline alertness may be noticed.
Stimulation builds steadily. Wakefulness and focus begin to sharpen. Mild mood elevation becomes apparent.
Maximum stimulation, focus enhancement, and motivation. Mood elevation is most pronounced. Cognitive euphoria and thought acceleration are at their clearest.
Stimulation persists at slightly reduced intensity. Focus and wakefulness remain functional and productive. The experience stabilizes without notable fluctuation.
Gradual tapering of stimulant effects. Wakefulness diminishes toward baseline. Focus slowly softens.
Residual wakefulness due to 21-hour elimination half-life. Subtle cognitive clarity or mild restlessness may persist. Sleep architecture is minimally disrupted at doses ≤400 mg if consumed >4 hours before bedtime.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Low
- Withdrawal
- None
- Tolerance buildup
- none
- Tolerance reset
- —
- Physical
- Negligible
- Psychological
- Low
- Compulsive redosing
- Low
- Dose escalation
- Negligible
- Cross-tol.
- caffeine
Toxicity
Acute toxicity
No lethal dose has been established for theacrine, and no overdose or serious adverse events have been published.safety citation needed Eight weeks of daily use at 200 mg and 300 mg produced no clinically significant changes in heart rate, blood pressure, blood counts, or markers of liver, kidney, or immune function.[7]
Cardiovascular effects at high doses
Blood pressure rises at doses above typical supplementation ranges. At approximately 6 mg/kg (around 420 mg for a 70 kg person), resting blood pressure is significantly elevated.[6] Reported side effects at 3–6 mg/kg include stomach discomfort, perceived heart racing, dizziness, headache, head pressure, and hand tremor.[6]
One study found no significant heart rate or blood pressure changes at 3, 6, or 9 mg/kg but observed elevated salivary cortisol at 120–180 minutes post-dose.[8]
Cortisol elevation
Salivary cortisol is elevated at doses of 3–9 mg/kg (approximately 210–630 mg for a 70 kg person) at 120–180 minutes after administration.[8] Whether this is clinically significant at typical supplementation doses (200–300 mg) has not been directly assessed.
Liver effects
Animal studies show decreased liver enzyme markers and reduced inflammation rather than harm.[20][21] No human liver toxicity has been reported.
Psychological risks
Theacrine has not been associated with significant psychological adverse effects at doses up to 300 mg/day. Anxiety was not elevated versus placebo in the 8-week safety trial,[7] and a caffeine–theacrine combination raised alertness without raising anxiety — unlike caffeine alone.[16]
At doses of 6 mg/kg or more, dizziness, head pressure, and general malaise are reported.[6] No psychotic, hallucinogenic, or dissociative effects have been reported at any dose studied. No data exist on psychological effects beyond the 8-week study horizon.
Tolerance and dependence
Theacrine's most pharmacologically distinctive feature is that it does not produce tolerance. Eight weeks of daily use at 200–300 mg produced no decline in energy, focus, concentration, or motivation.[7] Animal studies independently confirmed no tolerance or sensitization with chronic dosing.[2]
No withdrawal has been characterized and no formal abuse liability testing has been published. The absence of tolerance and sensitization is consistent with low dependence potential, though this has not been directly tested.
Drug Interactions
Caffeine. Co-administration raises theacrine's blood levels through enhanced absorption.[15] Heart rate and blood pressure are not additively elevated at typical combination doses.[15][22]
Methylliberine. Does not alter theacrine levels, but slows caffeine clearance — so the three-way combination increases caffeine exposure.[16]
Other stimulants. No published interaction data exist for theacrine with amphetamines, MDMA, or other stimulants. Additive cardiovascular and dopaminergic burden would be expected based on shared mechanisms.inferred
Adenosine-based medical procedures. Theacrine blocks adenosine receptors and would interfere with cardiac stress testing drugs (regadenoson, adenosine infusion), potentially invalidating test results. The 21-hour half-life[5] requires at least 4 days' washout before such procedures.inferred
CYP1A2 medications. If theacrine is metabolized by CYP1A2 — inferred from caffeine analogy, not confirmed — interactions with strong inhibitors such as fluvoxamine or ciprofloxacin, or sensitive substrates such as tizanidine, are theoretically possible.inferred
No published data exist for interactions with MAOIs, SSRIs, SNRIs, blood pressure medications, heart rhythm drugs, or sedatives.
Contraindications
5 knownNo formally published contraindications exist. The following are inferred from pharmacological mechanism and observed effects:
Heart conditions (relative). Blood pressure elevation at doses ≥6 mg/kg[6] and perceived heart racing suggest caution in individuals with uncontrolled high blood pressure, irregular heartbeat, or cardiovascular disease.inferred
Anxiety disorders (relative). Theacrine appears less anxiety-producing than caffeine at typical doses,[16] but its stimulant mechanism warrants caution in panic disorder or generalized anxiety disorder, particularly at higher doses.inferred
Stress hormone disorders (relative). Cortisol elevation at doses ≥3 mg/kg[8] suggests caution in individuals with Cushing's syndrome, adrenal insufficiency, or other conditions affecting the stress hormone system.inferred
Adenosine-dependent medical procedures (absolute). Discontinuation is required before adenosine-based cardiac stress testing. The 21-hour half-life[5] dictates a minimum washout of approximately 4 days.
Pregnancy and lactation. No reproductive or developmental toxicity data have been published.safety citation needed
Harm Reduction[edit]
Forms & Identification
Theacrine is sold primarily as encapsulated powder or as a component of pre-workout and nootropic supplement blends, most commonly as TeaCrine®. Standalone powder is white to off-white and crystalline.[23]
For standalone powder, a milligram-accurate scale is essential — volumetric estimation is unreliable because powder density varies between manufacturers. Blended products vary widely in theacrine content per serving; confirm the label specifies theacrine dosage separately from total blend weight.
Guidelines
- Start at the lower end of typical doses and assess response before increasing. Individual sensitivity varies, particularly with habitual caffeine intake.
- Dose in the morning. The prolonged half-life makes afternoon or evening dosing likely to interfere with sleep.
- Use a milligram-accurate scale for loose powder. Do not estimate doses by volume.
- Avoid combining with other stimulants until individual response is established.
- If scheduled for an adenosine-based cardiac stress test, discontinue theacrine at least 4 days before the procedure.
- Stay hydrated. Stimulant-driven focus can suppress awareness of thirst.
Set & Setting
Theacrine's effects are less context-sensitive than psychedelics or empathogens, but setting still shapes the experience. Stimulation in a structured, task-oriented environment tends to channel into sustained focus; without clear tasks, the same activation can become restlessness or agitation.
First-time users should trial theacrine on a day with flexible obligations. The 21-hour half-life means effects persist well beyond a typical caffeine window — afternoon dosing may impair sleep even when subjective stimulation feels mild by evening.
Habitual caffeine consumers should expect stronger theacrine effects due to caffeine's pharmacokinetic interaction.
Aftercare & integration. Theacrine's extended half-life means residual stimulation can persist for many hours after the perceived peak. If sleep is difficult, avoid additional caffeine and use standard sleep hygiene: dim lighting, cool room, no screens.
Stimulant comedowns with theacrine are generally mild compared to stronger stimulant classes. Adequate hydration, regular meals, and light physical activity support recovery. Persistent anxiety, restlessness, or elevated heart rate beyond 24 hours after the last dose warrants consultation with a healthcare provider.
Recovery & Support
Theacrine's dependence potential appears low — no tolerance, withdrawal, or compulsive use patterns have been documented. But any stimulant used habitually to manage fatigue, productivity, or mood can become psychologically entrenched.
If theacrine use has become a daily requirement to function, gradual tapering and addressing the underlying driver — chronic sleep deficit, burnout, or untreated mood conditions — is a sensible approach. A healthcare provider or counselor can help evaluate whether stimulant reliance is masking a treatable condition.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency. Most theacrine side effects are uncomfortable but not dangerous: stomach discomfort, jitteriness, headache, and mild dizziness are common at higher doses. Seek immediate medical attention for chest pain, sustained rapid or irregular heartbeat, difficulty breathing, seizure, or loss of consciousness.
Immediate steps:
- 1. Call emergency services if any red-flag symptoms are present.
- 2. Move the person to a calm, cool environment.
- 3. Do not induce vomiting.
- 4. Monitor breathing and consciousness until help arrives.
- 5. If the person is unconscious but breathing, place them in the recovery position.
What to tell the dispatcher: Name the substance (theacrine), approximate amount taken, time of ingestion, and current symptoms. If other substances were co-ingested (caffeine, pre-workout blends, other stimulants), report those as well. Good Samaritan laws in many jurisdictions protect people who call for help during a drug-related emergency.
Legal Status[edit]
Theacrine is unscheduled in all major jurisdictions as of 2026 and is commercially available worldwide as a dietary supplement ingredient.[9]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Unscheduled; dietary supplement ingredient | Not listed under the Controlled Substances Act. Commercially sold without FDA drug approval. No publicly documented New Dietary Ingredient notification. TeaCrine® holds U.S. patent US10272091B2.[9] |
| United Kingdom | Not scheduled | Not listed under the Misuse of Drugs Act 1971 or the Psychoactive Substances Act 2016. Sold freely as a supplement ingredient.citation needed |
| European Union | Not scheduled | Not listed as a controlled substance. Precise classification under the EU Novel Food Regulation (EC 2015/2283) has not been formally confirmed.citation needed |
| Canada | Not scheduled | Not listed under the Controlled Drugs and Substances Act. Available as a supplement ingredient. Health Canada Natural Product Number status not confirmed.citation needed |
| Australia | Not scheduled | Not listed in the Standard for the Uniform Scheduling of Medicines and Poisons. TGA classification not formally confirmed.citation needed |
| WADA | Not prohibited | Not on the 2025/2026 WADA Prohibited List. Used by competitive athletes in published studies.[6][24] |
Legal status changes frequently and varies by jurisdiction. This information reflects available data as of 2026 and does not constitute legal advice.
The Federal Analogue Act (21 U.S.C. § 813) does not apply — theacrine is a naturally occurring plant alkaloid with a distinct structure from any scheduled substance, and its closest relative (caffeine) is itself unscheduled.
Safety[edit]
- Acute toxicity
- Low
- Chronic toxicity
- Low
- Withdrawal
- None
- Tolerance buildup
- none
- Tolerance reset
- —
- Physical
- Negligible
- Psychological
- Low
- Compulsive redosing
- Low
- Dose escalation
- Negligible
- Cross-tol.
- caffeine
Toxicity
Acute toxicity
No lethal dose has been established for theacrine in any species, and no case reports of overdose or serious adverse events have been published.safety citation needed
Eight weeks of daily use at 200 mg and 300 mg produced no clinically significant changes in heart rate, blood pressure, blood counts, or liver, kidney, and immune markers.[6] Acute dosing at 200 mg similarly showed no changes in resting heart rate or oxygen consumption.[20] Caffeine co-administration at typical doses does not additively elevate cardiovascular parameters.[15]
Cardiovascular effects at high doses
Dose-dependent blood pressure elevation emerges above typical supplementation ranges. At approximately 6 mg/kg (~420 mg for a 70 kg individual), resting blood pressure is significantly elevated.[5] Side effects reported at 3–6 mg/kg include stomach discomfort, perceived heart racing, dizziness, headache, head pressure, and hand tremor.[5]
A separate study found no significant heart rate or blood pressure effects at 3, 6, or 9 mg/kg, but observed elevated salivary cortisol at 120–180 minutes post-dose.[21]
Cortisol elevation
Salivary cortisol is elevated at doses of 3–9 mg/kg (approximately 210–630 mg for a 70 kg individual) at 120–180 minutes after administration.[21] The significance of this stress hormone activation at typical supplementation doses (200–300 mg) has not been directly assessed.
Liver effects
Published data suggest protective rather than harmful liver effects. Animal studies show decreased liver enzyme markers, reduced inflammation, and reversed liver damage in stress and fatty liver disease models.[22][23] No human liver toxicity has been reported.
Psychological risks
Theacrine has not been associated with significant psychological adverse effects at doses up to 300 mg/day. Anxiety was not elevated relative to placebo in the 8-week safety trial.[6] A caffeine-theacrine combination increased alertness without increasing anxiety, whereas caffeine alone raised self-reported anxiety.[16]
At higher doses (≥6 mg/kg), side-effect reports include dizziness, head pressure, and general malaise that may have psychological dimensions.[5] No psychotic, hallucinogenic, or dissociative effects have been reported at any dose studied. No data exist on psychological effects beyond the 8-week study horizon.
Tolerance and dependence
Theacrine's most pharmacologically distinctive feature is its non-habituating profile. Eight weeks of daily use at 200–300 mg produced no decline in energy, focus, concentration, or motivation effects.[6] Animal studies independently confirmed no tolerance or sensitization with chronic dosing.[2] The mechanism underlying this non-habituating profile has not been established.
No formal abuse liability testing has been published, and no withdrawal has been characterized. The absence of tolerance and sensitization is consistent with low dependence potential, though this inference has not been directly tested.
Drug Interactions
Caffeine. Co-administration increases theacrine's blood levels through enhanced absorption.[15] Habitual caffeine consumers may experience stronger theacrine effects than caffeine-naive individuals. Heart rate and blood pressure are not additively elevated at typical combination doses.[15][24]
Methylliberine. Does not alter theacrine levels, but decreases caffeine clearance — meaning the three-way combination modifies caffeine exposure.[16]
Other stimulants. No published interaction data exist for theacrine with amphetamines, MDMA, or other stimulant drugs. Additive cardiovascular and dopaminergic burden would be expected based on shared mechanisms.inferred
Adenosine-based medical procedures. Theacrine's adenosine receptor blocking would interfere with cardiac stress testing drugs (regadenoson, adenosine infusion), potentially invalidating results. The 21-hour half-life[4] requires a minimum washout of approximately 4 days before such procedures.inferred
CYP1A2 medications. If theacrine is metabolized by CYP1A2 (structurally inferred, not confirmed), interactions with strong CYP1A2 inhibitors (fluvoxamine, ciprofloxacin) or sensitive CYP1A2 substrates (tizanidine) are theoretically possible.inferred
No published interaction data exist for theacrine with MAOIs, SSRIs, SNRIs, blood pressure medications, heart rhythm medications, or sedatives.
Contraindications
5 knownNo formally published contraindications exist. The following are inferred from pharmacological mechanism and observed effects:
Heart conditions (relative). Blood pressure elevation at doses ≥6 mg/kg[5] and perceived heart racing suggest caution in individuals with uncontrolled high blood pressure, irregular heartbeat, or other cardiovascular disease.inferred
Anxiety disorders (relative). Although theacrine appears less anxiety-producing than caffeine at typical doses,[16] its stimulant mechanism warrants caution in individuals with panic disorder or generalized anxiety disorder, particularly at higher doses.inferred
Stress hormone disorders (relative). Cortisol elevation at doses ≥3 mg/kg[21] suggests caution in individuals with Cushing's syndrome, adrenal insufficiency, or other HPA axis conditions.inferred
Adenosine-dependent medical procedures (absolute). Discontinuation is required before adenosine-based cardiac stress testing, with the 21-hour half-life[4] dictating a minimum washout of approximately 4 days.
Pregnancy and lactation. No reproductive or developmental toxicity data have been published.safety citation needed
Harm Reduction[edit]
Forms & Identification
Theacrine is commercially available primarily as encapsulated powder or as a component of pre-workout and nootropic supplement blends, most commonly under the TeaCrine® brand. The structured module above shows common forms and identification data. For standalone powder, an accurate milligram scale is essential — volumetric estimation is unreliable due to variable powder density between manufacturers. Blended products vary widely in theacrine content per serving; confirm the label specifies theacrine dosage separately from total blend weight.
Guidelines
- Start at the lower end of typical doses and assess response before increasing. Individual sensitivity varies, particularly with habitual caffeine intake.
- Dose in the morning. The prolonged half-life makes afternoon or evening dosing likely to interfere with sleep.
- Use a milligram-accurate scale for loose powder. Do not estimate doses by volume.
- Avoid combining with other stimulants until individual response is established.
- If scheduled for an adenosine-based cardiac stress test, discontinue theacrine at least 4 days before the procedure.
- Stay hydrated. Stimulant-driven focus can suppress awareness of thirst.
Set & Setting
Theacrine's stimulant effects are relatively context-independent compared to psychedelic or empathogenic compounds, but setting still shapes the experience. Stimulation in a productive environment tends to channel into sustained focus; the same activation without structured tasks can manifest as restlessness or agitation.
First-time users should trial theacrine on a day with flexible obligations. The 21-hour half-life means effects persist well beyond a typical caffeine window — afternoon dosing may impair sleep even if subjective stimulation feels mild by evening. Individuals who consume caffeine regularly should expect enhanced theacrine effects due to caffeine's pharmacokinetic interaction.
Aftercare & integration. Theacrine's extended half-life means residual stimulation can persist for many hours after the perceived peak has passed. If sleep is difficult, avoid additional caffeine and use standard sleep hygiene: dim lighting, cool room, no screens.
Stimulant comedowns with theacrine are generally mild compared to stronger stimulant classes. Adequate hydration, regular meals, and light physical activity support recovery. If persistent anxiety, restlessness, or elevated heart rate continue beyond 24 hours after the last dose, consult a healthcare provider.
Recovery & Support
Theacrine's dependence potential appears low based on current evidence — no tolerance, withdrawal, or compulsive use patterns have been documented. However, any stimulant used habitually to manage fatigue, productivity, or mood can become psychologically entrenched.
If theacrine use has become a daily requirement to function, consider tapering gradually and addressing the underlying driver — chronic sleep deficit, burnout, or untreated mood conditions. A healthcare provider or counselor can help evaluate whether stimulant reliance is masking a treatable condition.
Recovery resources, crisis lines, and support pathways → View all
Emergency Response
Recognizing an emergency. Most theacrine side effects are uncomfortable but not dangerous: stomach discomfort, jitteriness, headache, and mild dizziness are common at higher doses. Seek immediate medical attention for chest pain, sustained rapid or irregular heartbeat, difficulty breathing, seizure, or loss of consciousness.
Immediate steps:
- 1. Call emergency services if any red-flag symptoms are present.
- 2. Move the person to a calm, cool environment.
- 3. Do not induce vomiting.
- 4. Monitor breathing and consciousness until help arrives.
- 5. If the person is unconscious but breathing, place them in the recovery position.
What to tell the dispatcher: Name the substance (theacrine), approximate amount taken, time of ingestion, and current symptoms. If other substances were co-ingested (caffeine, pre-workout blends, other stimulants), report those as well. Good Samaritan laws in many jurisdictions protect people who call for help during a drug-related emergency.
Legal Status[edit]
Theacrine is unscheduled in all major jurisdictions as of 2026. No national regulatory authority has classified it as a controlled substance or initiated scheduling proceedings. It is commercially available worldwide as a dietary supplement ingredient, marketed primarily under the TeaCrine® brand.[8]
| Jurisdiction | Classification | Key provisions |
|---|---|---|
| United States | Unscheduled; dietary supplement ingredient | Not listed under the Controlled Substances Act. Commercially sold without FDA drug approval. No publicly documented New Dietary Ingredient notification. TeaCrine® holds U.S. patent US10272091B2.[8] |
| United Kingdom | Not scheduled | Not listed under the Misuse of Drugs Act 1971 or the Psychoactive Substances Act 2016. Sold freely as a supplement ingredient.citation needed |
| European Union | Not scheduled | Not listed as a controlled substance. Precise classification under the EU Novel Food Regulation (EC 2015/2283) has not been formally confirmed.citation needed |
| Canada | Not scheduled | Not listed under the Controlled Drugs and Substances Act. Available as a supplement ingredient. Health Canada Natural Product Number status not confirmed.citation needed |
| Australia | Not scheduled | Not listed in the Standard for the Uniform Scheduling of Medicines and Poisons. TGA classification not formally confirmed.citation needed |
| WADA | Not prohibited | Not on the 2025/2026 WADA Prohibited List. Used by competitive athletes in published studies.[5][25] |
The Federal Analogue Act (21 U.S.C. § 813) does not apply — theacrine is a naturally occurring plant alkaloid with a distinct chemical structure from any scheduled substance, and its primary structural relative (caffeine) is itself unscheduled.
Frequently asked questions
What is Theacrine?
Theacrine is a methylurate purine alkaloid and stimulant that acts as an adenosine A1/A2A receptor antagonist with dopaminergic involvement. Distinguished from caffeine by a non-habituating profile over weeks of daily use and an elimination half-life of approximately 21 hours.
How long does Theacrine last?
Total duration by route of administration — Insufflated: 1 – 3 hours; Oral: 6 – 10 hours. Ranges vary with dose and individual factors; see the duration table for onset, peak, and after-effect phases.
Where can I find dosage information for Theacrine?
Psychedex publishes a dosage table for Theacrine on this page covering these routes of administration: oral, insufflated. Dose values are presented only in that table, always alongside their route of administration.
What are dangerous combinations with Theacrine?
The highest-severity documented interactions for Theacrine: Amphetamines (Dangerous), CBD (Dangerous), Ephedrine, Pseudoephedrine (Dangerous), GHB, Baclofen (Dangerous), GHB, GBL (Dangerous). See the interactions section for the full list with mechanisms and severity levels.
Is Theacrine addictive?
Psychedex records tolerance and dependence data rather than a yes/no rating. Recorded tolerance indicators for Theacrine: tolerance builds none; cross-tolerance develops with caffeine. See the article's dependence and safety sections for recorded dependence data.
experience reports
No experience reports yet. Be the first to contribute.
First-person accounts of subjective effects, timing, and outcomes — submitted for harm reduction.
references
- [1] ^abcZhang YH, Li YF, Wang Y, Tan L, Cao Z (2020) Identification and characterization of N9-methyltransferase involved in converting caffeine into non-stimulatory theacrine in tea. — Nature Communications doi:10.1038/s41467-020-15324-7
- [2]
- [3]
- [4]
- [5]
- [6]
references
- [1] ^abcZhang YH, Li YF, Wang Y, Tan L, Cao Z (2020) Identification and characterization of N9-methyltransferase involved in converting caffeine into non-stimulatory theacrine in tea. — Nature Communications doi:10.1038/s41467-020-15324-7
- [2] ^abcdefghiFeduccia AA, Wang Y, Simms JA, Yi HY, Li R, Bjeldanes L, Ye C, Bartlett SE (2012) Locomotor activation by theacrine, a purine alkaloid structurally similar to caffeine: involvement of adenosine and dopamine receptors. — Pharmacology, Biochemistry, and Behavior doi:10.1016/j.pbb.2012.04.014
- [3]
- [4]
- [5]
- [6]